For those with the PMS2 pathogenic variant, endometrial cancer may develop later, and the cancer risk is often lower than that of individuals with the other three pathogenic variants, with a cumulative incidence of 0 before age 50 and 9.3%-12.8% at age 60–70 [20]. The gene discussed is PMS2; the disease is cancer.